SIE-1

2025-523269-31-00 · tracked via the Priya Life Science EU tracker

Sponsor

Laboratorios Farmaceuticos Rovi S.A.

Sponsor type

Pharmaceutical company

Therapeutic area

Neoplasms

Decision date

31/03/2026

Enrollment target

Sites

Spain

Condition studied

Hormone receptor-positive early breast cancer in post-menopausal women

Eligibility

Age group

18-64 years, 65+ years

Sex

Female

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-523269-31-00 on CTIS ↗ ← All trials in the EU